Editas Medicine upgraded by BofA Securities with a new price target

8/8/24 6:59:16 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

BofA Securities upgraded Editas Medicine from Neutral to Buy and set a new price target of $15.00 from $13.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$EDIT

Date	Price Target	Rating	Analyst
4/28/2025	$3.00	Buy	H.C. Wainwright
12/16/2024		Neutral → Underweight	Analyst
12/13/2024		Buy → Neutral	Chardan Capital Markets
12/13/2024		Buy → Hold	Truist
12/13/2024	$11.00 → $3.00	Buy → Hold	Stifel
12/11/2024	$7.00 → $4.00	Overweight → Equal Weight	Wells Fargo
11/25/2024	$13.00 → $1.00	Buy → Underperform	BofA Securities
11/6/2024		In-line → Outperform	Evercore ISI